左西孟旦对慢性心力衰竭患者心肌缺血及病情进展的影响

doi:10.3760/cma.j.issn.1007-1245.2024.12.022

摘要/Abstract

摘要：

目的　观察左西孟旦治疗慢性心力衰竭（CHF）对患者心肌功能及病情进展的影响。方法　本研究为随机对照试验，选取2020年5月至2023年3月郑州市第七人民医院收治的CHF患者125例，采用电脑分组法将其分为常规组（62例）和联合组（63例）。常规组男30例，女32例；年龄52～78（65.44±5.18）岁；CHF病程3～7（5.25±1.33）年；心功能分级：Ⅱ级33例，Ⅲ级29例；合并症：35例合并高血压，27例合并糖尿病；采用常规药物治疗。联合组男33例，女30例；年龄50～80（65.75±5.33）岁；CHF病程4～6（5.31±1.28）年；心功能分级：Ⅱ级32例，Ⅲ级31例；合并症：38例合并高血压，25例合并糖尿病；采用左西孟旦（静脉注射）配合常规治疗。两组均治疗15 d。比较两组患者治疗前和治疗15 d后的心肌功能［可溶性生长刺激表达基因2蛋白（sST2）、生长分化因子15（GDF-15）］、心肌纤维化指标［结缔组织生长因子（CTGF）、层黏连蛋白（LN）、透明质酸（HA）］、心功能指标［左心室射血分数（LVEF）、每搏输出量（SV）、心排血量（CO）］变化情况，治疗后3个月的心血管不良事件发生情况及用药安全性。采用独立样本t检验、配对样本t检验和χ²检验。结果　治疗后，联合组sST2［（86.24±10.35）μg/L］和GDF-15［（814.36±50.25）ng/L］均低于常规组［（92.37±10.41）μg/L、（841.72±50.47）ng/L］（均P<0.05）；联合组CTGF［（1.04±0.52）μg/L］、LN［（103.52±10.32）μg/L］和HA［（95.15±10.36）μg/L］均低于常规组［（1.77±0.36）μg/L、（110.75±10.25）μg/L、（102.77±10.65）μg/L］（均P<0.05）；联合组LVEF［（55.41±10.28）%］、SV［（58.72±10.45）ml］和CO［（4.52±1.36）L/min］均高于常规组［（49.14±10.33）%、（52.33±10.06）ml、（3.77±0.82）L/min］（均P<0.05）；联合组的心血管不良事件总发生率［4.76%（3/63）］低于常规组［16.13%（10/62）］（P<0.05）；两组药物相关不良反应总发生率比较，差异无统计学意义（P>0.05）。结论　左西孟旦可有效改善CHF患者心肌功能并延缓心肌纤维化病程，在改善患者心功能的同时，可一定程度上降低心血管不良事件发生风险；且此药安全性较高，未明显增加患者用药后的相关不良反应发生风险。

关键词:

慢性心力衰竭, 左西孟旦, 心肌功能, 心肌纤维化, 用药安全性

Abstract:

Objective　To observe the effect of Levosimendan on myocardial function and disease progression in patients with chronic heart failure (CHF). Methods　This study was a randomized controlled trial. A total of 125 CHF patients admitted to Zhengzhou Seventh People's Hospital from May 2020 to March 2023 were selected and were divided into a conventional group (62 cases) and a combined group (63 cases) by the computer grouping method. In the conventional group, there were 30 males and 32 females, the age was 52-78 (65.44±5.18) years old, the course of CHF was 3-7 (5.25±1.33) years, the cardiac function classification was grade II in 33 cases and grade III in 29 cases, and the complications included hypertension in 35 cases and diabetes in 27 cases. There were 33 males and 30 females in the combined group, the age was 50-80 (65.75±5.33) years old, the course of CHF was 4-6 (5.31±1.28) years, the cardiac function classification was grade II in 32 cases and grade III in 31 cases, and the complications included hypertension in 38 cases and diabetes in 25 cases. The conventional group was treated with conventional medicine, and the combined group was treated with Levosimendan via intravenous injection combined with conventional medicine for 15 d. The changes in myocardial function [soluble growth stimulator expression gene 2 protein (sST2) and growth differentiation factor 15 (GDF-15)], myocardial fibrosis indicators [connective tissue growth factor (CTGF), laminin (LN), and hyaluronic acid (HA)], and cardiac function indexes [left ventricular ejection fraction (LVEF), stroke output (SV), and cardiac output (CO)] before and after treatment, as well as occurrence of adverse cardiovascular events within 3 months after treatment and medication safety were compared between the two groups. Independent sample t test, paired t test, and χ² test were used. Results　After treatment, the levels of sST2 [(86.24±10.35) μg/L] and GDF-15 [(814.36±50.25) ng/L] in the combined group were lower than those in the conventional group [(92.37±10.41) μg/L and (841.72±50.47) ng/L](both P<0.05), the levels of CTGF [(1.04±0.52) μg/L], LN [(103.52±10.32) μg/L], and HA [(95.15±10.36) μg/L] in the combined group were lower than those in the conventional group [(1.77±0.36) μg/L, (110.75±10.25) μg/L, and (102.77±10.65) μg/L](all P<0.05), and the levels of LVEF [(55.41±10.28)%], SV [(58.72±10.45) ml], and CO [(4.52±1.36) L/min] in the combined group were higher than those in the conventional group [(49.14±10.33)%, (52.33±10.06) ml, and (3.77±0.82) L/min] (all P<0.05). The total incidence of adverse cardiovascular events in the combined group [4.76% (3/63)] was lower than that in the conventional group [16.13% (10/62)] (P<0.05). There was no statistically significant difference in the total incidence of drug-related adverse reactions between the two groups (P>0.05). Conclusions　Levosimendan can effectively improve the myocardial function of CHF patients and delay the course of myocardial fibrosis. It has positive significance in promoting the patients' cardiac function recovery and reducing the risk of cardiovascular adverse events. Moreover, this drug has high safety and does not significantly increase the risk of drug-related adverse reactions.

Key words:

Chronic heart failure, Levosimendan, Myocardial function, Myocardial fibrosis, Drug safety

汤光耀.

左西孟旦对慢性心力衰竭患者心肌缺血及病情进展的影响 [J]. 国际医药卫生导报, 2024, 30(12): 2044-2048.

Tang Guangyao.

Effects of Levosimendan on myocardial ischemia and disease progression in patients with chronic heart failure [J]. International Medicine and Health Guidance News, 2024, 30(12): 2044-2048.

参考文献

[1] 王莹,刘莹,袁莹,等.铁缺乏伴或不伴贫血症状与老年慢性心力衰竭患者左心室射血分数、运动耐量的关系及对生活质量的影响[J].岭南心血管病杂志,2021,27(6):693-699.DOI:10.3969/j.issn.1007-9688.2021.06.12.
[2] Austin RC, Schoonhoven L, Koutra V, et al. SYMptoms in chronic heart failure imPACT on burden of treatment (SYMPACT): a cross-sectional survey[J]. ESC Heart Fail, 2022, 9(4):2279-2290. DOI: 10.1002/ehf2.13904.
[3] 郭智星,高传玉.慢性心力衰竭药物治疗研究进展[J].中国心血管病研究,2022,20(12):1129-1134.DOI:10.3969/j.issn.1672-5301.2022.12.013.
[4] 王元芬,詹鹏,黄青,等.老年心力衰竭患者心电异常活动程度与左心室心肌收缩功能的相关性[J].中国老年学杂志,2021,41(4):696-698.DOI:10.3969/j.issn.1005-9202. 2021.04.008.
[5] 王新婷,鲁成,宋磊,等.AACO方调控TGF-β1/Smad3信号通路保护慢性心力衰竭小鼠心肌纤维化的作用机制研究[J].中国中医药信息杂志,2023,30(1):103-108.DOI:10.19879/j.cnki.1005-5304.202204199.
[6] 朱子雄,李学文.左西孟旦治疗心力衰竭研究进展[J].中西医结合心脑血管病杂志,2023,21(5):863-865.DOI:10.12102/j.issn.1672-1349.2023.05.019.
[7] Caraballo C, Desai NR, Mulder H, et al. Clinical implications of the New York Heart Association classification[J]. J Am Heart Assoc, 2019, 8(23):e014240. DOI: 10.1161/JAHA.119.014240.
[8] 王志燕,陈晨,吕强,等.2021年ESC急慢性心力衰竭诊断与治疗指南解读[J].中华心血管病杂志,2021,49(12):1252-1255.DOI:10.3760/cma.j.cn112148-20210929- 00840.
[9] 潘锋.心衰高风险人群需早期预防和规范治疗[J].中国医药导报,2022,19(36):1-3.
[10] 李萌,雷帅,张陈平,等.心力衰竭药物治疗的研究进展[J].中国医科大学学报,2022,51(5):455-458.DOI:10.12007/j.issn.0258-4646.2022.05.014.
[11] 廖荣华,谢恒元,江春玲,等.心力衰竭治疗药物的临床应用进展[J].中国新药与临床杂志,2022,41(4):193-200.DOI:10.14109/j.cnki.xyylc.2022.04.01.
[12] Janssen PML. Myocardial relaxation in human heart failure: why sarcomere kinetics should be center-stage[J]. Arch Biochem Biophys, 2019, 661:145-148. DOI: 10.1016/j.abb.2018.11.011.
[13] 邢布点,魏婷,卢园园,等.IL?33/sST2信号通路与原发性高血压左室肥厚患者的相关性研究[J].海南医学院学报,2022,28(21):1621-1626.DOI:10.13210/j.cnki.jhmu.20220816.004.
[14] 王昱冕,陈涵,王红.生长分化因子15与心血管疾病出血事件相关性的研究进展[J].心血管病学进展,2022,43(10):928-931,946.DOI:10.16806/j.cnki.issn.1004-3934.2022. 10.015.
[15] Li M, Zhang Y, Wan Q, et al. Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study[J]. BMC Cardiovasc Disord, 2022, 22(1):130. DOI: 10.1186/s12872-022-02572-2.
[16] 刘亚丽,李春彦,李雅丽,等.左西孟旦对大鼠急性心肌梗死后心肌纤维化及心功能的影响[J].中国临床解剖学杂志,2022,40(1):49-54.DOI:10.13418/j.issn.1001- 165x.2022.1.10.
[17] 林显营,莫秀丽,方柏.美托洛尔联合左西孟旦对慢性心力衰竭患者血清学指标及心肌纤维化标志物的影响[J].中国医药科学,2022,12(4):77-79,83.DOI:10.3969/j.issn.2095-0616.2022.04.021.
[18] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use[J]. J Cardiovasc Pharmacol, 2020, 76(1):4-22. DOI: 10.1097/FJC.0000000000000859.
[19] 王欢.左西孟旦联合地高辛治疗老年退行性心脏瓣膜病合并心力衰竭对患者心功能及运动耐力的影响[J].当代医药论丛,2023,21(4):103-105.DOI:10.3969/j.issn.2095-7629. 2023.04.032.
[20] 李晓光,张妍,翟所迪,等.左西孟旦注射液在中国健康人体的药代动力学[J].中国临床药理学杂志,2012,28(2):110-114.DOI:10.3969/j.issn.1001-6821.2012.02.010.